William Blair Weighs in on Avantor’s Q3 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Stock analysts at William Blair lowered their Q3 2025 earnings estimates for shares of Avantor in a report issued on Friday, February 7th. William Blair analyst M. Larew now anticipates that the company will post earnings of $0.28 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. William Blair also issued estimates for Avantor’s FY2025 earnings at $1.11 EPS.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter last year, the company earned $0.22 EPS.

AVTR has been the topic of a number of other reports. Royal Bank of Canada lowered their target price on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Monday. Morgan Stanley decreased their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday. Stifel Nicolaus dropped their price objective on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $24.00 price target (down previously from $26.00) on shares of Avantor in a research report on Monday. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.15.

Avantor Stock Down 3.1 %

AVTR stock opened at $18.42 on Monday. The stock’s 50 day simple moving average is $21.68 and its 200 day simple moving average is $23.44. The company has a market cap of $12.53 billion, a P/E ratio of 40.03, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor has a fifty-two week low of $18.19 and a fifty-two week high of $28.00.

Hedge Funds Weigh In On Avantor

A number of hedge funds and other institutional investors have recently made changes to their positions in AVTR. Louisiana State Employees Retirement System raised its position in Avantor by 0.3% in the fourth quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock worth $3,980,000 after acquiring an additional 500 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock worth $644,000 after purchasing an additional 503 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Avantor by 6.9% in the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock worth $170,000 after purchasing an additional 522 shares during the period. Pacer Advisors Inc. lifted its stake in Avantor by 0.5% in the fourth quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after purchasing an additional 542 shares during the last quarter. Finally, Veracity Capital LLC grew its holdings in Avantor by 1.0% during the third quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock valued at $1,355,000 after purchasing an additional 543 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.